Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer

RABINOVICH, GABRIEL A.; RABINOVICH, GABRIEL A.; GIROTTI, MARÍA ROMINA; GIROTTI, MARÍA ROMINA; SALATINO, MARIANA; SALATINO, MARIANA

CANCER CELL

CELL PRESS

Año: 2018 vol. 33 p. 155 - 157

1535-6108

The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment. The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment.